An Open-label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Afuresertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 11 Jan 2018 Planned end date changed from 27 Dec 2017 to 30 Jun 2018.
- 11 Jan 2018 Planned primary completion date changed from 21 Jul 2017 to 30 Jun 2018.
- 22 May 2017 Planned End Date changed from 10 Oct 2017 to 27 Dec 2017.